Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men

PHASE3CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

April 30, 2018

Primary Completion Date

February 19, 2019

Study Completion Date

February 21, 2019

Conditions
Hypogonadism, Male
Interventions
DRUG

LPCN 1021

LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.

Trial Locations (16)

10016

Manhattan Medical Research Practice PLLC, New York

11530

AccuMed Research Associates, Garden City

32223

Jacksonville Impotence Treatment Center, Jacksonville

32765

Oviedo Medical Research, LLC, Oviedo

33012

Neostart Corporation dba AGA Clinical Trials, Hialeah

33060

Clinical Research Center of Florida, Pompano Beach

33134

Clinical Research of South Florida, Coral Gables

33180

South Florida Medical Research, Aventura

35235

Alabama Clinical Therapeutics, Birmingham

37203

Clinical Research Associates, Inc., Nashville

40509

Central Kentucky Research Associates, Inc., Lexington

43213

Aventiv Research, Inc., Columbus

45005

Prestige Clinical Research, Franklin

71106

Regional Urology, Shreveport

84096

Granger Medical Clinic, West Valley City

98057

Rainier Clinical Research Center, Renton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Lipocine Inc.

INDUSTRY

NCT03868059 - Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men | Biotech Hunter | Biotech Hunter